Royalty Pharma News

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TipRanksMay 10 11:17 ET

Royalty Pharma Analyst Ratings

BenzingaApr 12 08:01 ET

Teva Upgraded at J.P. Morgan on Upcoming Catalysts

Seeking AlphaMar 8 10:21 ET

JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating

MT NewswiresFeb 20 11:43 ET

Royalty Pharma Analyst Ratings

BenzingaFeb 20 10:36 ET

Analysts Are Bullish on Top Healthcare Stocks: Royalty Pharma (RPRX), Pro Medicus Limited (PMCUF)

TipRanksFeb 20 07:10 ET

Goldman Sachs Reaffirms Their Buy Rating on Royalty Pharma (RPRX)

TipRanksFeb 16 10:35 ET

Buy Rating Affirmed for Royalty Pharma on Strong Financials and Growth Prospects

TipRanksFeb 16 05:08 ET

Buy Rating Affirmed for Royalty Pharma on Strong Growth and Strategic Positioning

TipRanksJan 10 05:37 ET

Analysts Are Bullish on Top Healthcare Stocks: Incyte (INCY), Royalty Pharma (RPRX)

TipRanksNov 14, 2023 08:02 ET

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $57

BenzingaNov 9, 2023 09:37 ET

Royalty Pharma Analyst Ratings

BenzingaNov 9, 2023 09:37 ET

Strong Q3 Performance and Positive Outlook Boosts Royalty Pharma's Buy Rating: An Analysis by Chris Shibutani

TipRanksNov 9, 2023 08:35 ET

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Bristol-Myers Squibb (BMY) and Edwards Lifesciences (EW)

TipRanksOct 20, 2023 04:40 ET

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $54

BenzingaOct 11, 2023 10:51 ET

Royalty Pharma Analyst Ratings

BenzingaOct 11, 2023 10:50 ET

Goldman Sachs Sticks to Its Buy Rating for Royalty Pharma (RPRX)

TipRanksSep 5, 2023 23:35 ET

Goldman Sachs Keeps Their Buy Rating on Royalty Pharma (RPRX)

TipRanksAug 24, 2023 22:45 ET

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $53

BenzingaAug 9, 2023 10:56 ET

Royalty Pharma Analyst Ratings

BenzingaAug 9, 2023 10:55 ET